DYNE-101 + Placebo
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myotonic Dystrophy Type 1 (DM1)
Conditions
Myotonic Dystrophy Type 1 (DM1)
Trial Timeline
Sep 5, 2022 → Jul 1, 2029
NCT ID
NCT05481879About DYNE-101 + Placebo
DYNE-101 + Placebo is a phase 1/2 stage product being developed by Dyne Therapeutics for Myotonic Dystrophy Type 1 (DM1). The current trial status is recruiting. This product is registered under clinical trial identifier NCT05481879. Target conditions include Myotonic Dystrophy Type 1 (DM1).
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07486934 | Phase 3 | Recruiting |
| NCT05481879 | Phase 1/2 | Recruiting |
Competing Products
16 competing products in Myotonic Dystrophy Type 1 (DM1)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tideglusib | AMO Pharma | Pre-clinical | 15 |
| Tideglusib | AMO Pharma | Phase 2 | 44 |
| Tideglusib + Placebo | AMO Pharma | Phase 2/3 | 57 |
| Tideglusib | AMO Pharma | Phase 2/3 | 57 |
| VX-670 | Vertex Pharmaceuticals | Phase 2 | 51 |
| VX-670 + Placebo | Vertex Pharmaceuticals | Phase 1/2 | 40 |
| SAR446268 | Sanofi | Phase 1/2 | 40 |
| rhIGF-I/rhIGFBP-3 + placebo | Insmed | Phase 2 | 49 |
| IONIS-DMPKRx + Placebo | Ionis Pharmaceuticals | Phase 1/2 | 38 |
| Del-desiran (AOC 1001) | Avidity Biosciences | Phase 3 | 74 |
| ARO-DM1 Intravenous (IV) Infusion + Placebo Intravenous (IV) Infusion + ARO-DM1 subcutaneous (SC) injection + Placebo Subcutaneous (SC) Injection | Arrowhead Pharmaceuticals | Phase 1/2 | 38 |
| DYNE-101 + Placebo | Dyne Therapeutics | Phase 3 | 72 |
| Pitolisant Oral Tablet + Placebo oral tablet | Harmony Biosciences | Phase 2 | 47 |
| PGN-EDODM1 | PepGen | Phase 2 | 44 |
| PGN-EDODM1 | PepGen | Phase 2 | 44 |
| PGN-EDODM1 for infusion | PepGen | Phase 1 | 25 |